celecoxib has been researched along with farnesol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aizman, E; Kloog, Y; Mor, A | 1 |
| Chen, M; Goodin, S; Li, D; Liu, W; Ma, Y; Ren, X; Sheng, Z; Xu, X; Zhang, K; Zheng, X; Zhou, R | 1 |
2 other study(ies) available for celecoxib and farnesol
| Article | Year |
|---|---|
Celecoxib enhances the anti-inflammatory effects of farnesylthiosalicylic acid on T cells independent of prostaglandin E(2) production.
Topics: Animals; Celecoxib; Cell Adhesion; Cell Line; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Farnesol; Humans; Interleukin-2; Jurkat Cells; Mice; Mice, Inbred BALB C; Oncogene Protein p21(ras); Phosphorylation; Pyrazoles; Salicylates; Sulfonamides; T-Lymphocytes | 2012 |
Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Farnesol; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Salicylates; Signal Transduction | 2020 |